Toggle light / dark theme

Experimental AML vaccine linked to nine-month median survival gain in company-reported Phase 3 results

An experimental cancer vaccine called galinpepimut-S lowered the risk of death by 41% compared with best available treatment in a Phase 3 trial of people with acute myeloid leukemia (AML) in remission, drugmaker SELLAS Life Sciences reported Nov. 17 in a regulatory filing and press release. The results are company-reported topline data and have not been peer-reviewed.

Patients who received the vaccine lived a median of 24.0 months, compared with 14.7 months for those given best available treatment. The trial, called REGAL, enrolled 126 patients whose leukemia had returned, who had reached a second or later complete remission and who could not undergo a stem cell transplant.

For families of AML patients in that position, the options for staying in remission are limited, and relapse is common. A vaccine that adds months of survival with mostly mild side effects would matter, but the announcement leaves out key details that doctors will need to judge how large and reliable the benefit is.

Leave a Comment

Lifeboat Foundation respects your privacy! Your email address will not be published.